Introduction {#Sec1}
============

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease characterized by joint destruction and disability \[[@CR1]\]. The role of proinflammatory cytokines is well-defined in the mechanism of disease in local damage such as pannus formation and bone erosion \[[@CR1]\]. In addition, proinflammatory cytokines might contribute to the development of metabolic dysfunction in RA \[[@CR2]\]. Adipokines have gained a prominent role within the last decade in the understanding of pathogenesis of chronic diseases (RA, obesity, metabolic syndrome and type 2 diabetes mellitus) \[[@CR1], [@CR3]\], through the maintenance of chronic inflammation within the joints or systemically \[[@CR4]\]. From the adipokines described so far, the role of leptin is prominent.

Leptin is a non-glycosylated 16 kDa protein from the type I cytokine superfamily that is mainly produced by adipose tissue \[[@CR5], [@CR6]\]. Besides the biological function of leptin in food intake and energy expenditure, its role in immune regulation has been acknowledged due to its effects in both innate and adaptive immunity \[[@CR4], [@CR7]\]. Leptin signaling is transduced by leptin receptor (LepR), a transmembrane protein of 170 kDa that belongs to the family of type 1 cytokine receptors. Five isoforms of LepR in humans have been described; the isoforms "a" through "d", are transmembrane proteins obtained by alternative splicing, while, isoform "e" corresponds to soluble leptin receptor (sLepR) obtained by proteolytic shedding of transmembrane isoforms \[[@CR8]\].

sLepR could regulate leptin action through high affinity binding of free leptin, preventing its degradation and clearance, but also by avoiding leptin binding to transmembrane receptors and activation of signaling through the signal transducer and activator of transcription 3 protein (STAT3) \[[@CR9]--[@CR11]\]. Increased expression of sLepR is associated with lower body weight in murine models, suggesting the important role of sLepR in leptin regulation \[[@CR12]\]. Reduction of sLepR levels occur in progression of obesity with fat mass accumulation, turns into more bioactive leptin for signaling through transmembrane receptors \[[@CR13]--[@CR15]\]. Chronically high levels of leptin may provoke reduced LepR signaling due to a mechanism that is not yet completely elucidated, leading to leptin resistance \[[@CR16], [@CR17]\].

Despite the extensive study of leptin in RA there is still no consensus on the role of this molecule in RA pathogenesis. Previous studies included small numbers of patients without a clear cutoff for body mass index (BMI), resulting in non-reproducible associations. In general, serum levels of leptin are more elevated in RA patients than controls and are correlated with body fat mass and BMI \[[@CR18]--[@CR20]\]. Leptin levels are lower in synovial fluid than in plasma and correlate with intra-articular white blood cell count suggesting *in situ* consumption \[[@CR21]\]. Moreover, in vitro leptin may induce production of interleukin (IL)-6 in fibroblast-like synoviocytes and IL-8 via janus kinase (JAK)2-STAT3 signaling \[[@CR22], [@CR23]\]. In vivo, leptin has been correlated with erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), change in disease activity score in 28 joints (DAS28), erosive disease and progression in the Sharp/van der Heijde score \[[@CR24]--[@CR27]\].

In this study, we evaluated RA patients without traditional cardiovascular risk factors classified by anti-cyclic citrullinated peptide (anti-CCP) positivity, measuring serum leptin (sLep), sLepR, sLep/sLepR ratio and other metabolic parameters, namely proinflammatory cytokines, BMI and adiposity.

Methods {#Sec2}
=======

Study groups {#Sec3}
------------

We included patients with RA attending the rheumatology service of Hospital Civil "Dr. Juan I. Menchaca", Guadalajara, Jalisco, Mexico. To be eligible for the study, patients had to be 18 years of age or older and meet the American College of Rheumatology criteria (ACR 1987) \[[@CR28]\]. For the control group we included volunteers from the open population, who were matched by age, gender and BMI with the RA subjects. We excluded subjects with: previous history of smoking or who were current smokers; cardiovascular disease (CVD); hypertension; diabetes mellitus type 2; thyroid disease; renal impairment; malignancy; hepatic disease or hyperlipidemia. We also excluded patients previously treated with high doses of steroids (\>10 mg/day prednisone or equivalent, including those given by intravenous administration).

Ethics {#Sec4}
------

This protocol was approved by the Institutional Review Board (IRB) committee of "Hospital Civil Juan I. Menchaca", registered under the number 1068/10. Written consent was obtained from all subjects who participated in the study. Research was conducted according to Declaration of Helsinki.

Subject assessment {#Sec5}
------------------

Height was measured using a stadiometer (Seca GmbH & Co. KG. Hamburg, Germany) to the nearest 1.0 mm. Body weight (to the nearest 0.01 kg), BMI and fat mass were determined by bio-electrical impedance analysis (Tanita BC418® Tokyo, Japan). All subjects were classified by BMI according to World Health Organization (WHO) criteria as: normal weight (BMI 18.50--24.99 kg/m^2^), preobese (BMI 25.00--29.99 kg/m^2^) or obese (BMI ≥30.00 kg/m^2^) \[[@CR29]\]. Sagittal abdominal diameter (SAD) and waist and hip circumference were measured to the nearest 0.1 cm using an anthropometric fiberglass tape, Gulick® length 0--180 cm precision ±1 mm (North Coast Medical Inc., Gilroy, CA, USA) in accordance with the procedures recommended by Durnnin \[[@CR30]\]. Four measures (in millimeters) of skinfold thickness (biceps, triceps, subscapular and supra-iliac) were obtained on the left side of the body using a Harpenden skinfold caliper (opened 80 mm and precision of ± 0.2 mm, constant pressure 10 g/mm^2^; Holtain Ltd. Crosswell, Crymych, UK.) and following the procedures recommended by the anthropometric indicators measurement guide.
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as an indicator of preferential accumulation of fat in the abdomen rather than on the limbs, and the sum of the four skinfold thicknesses (S4ST) as an indicator of subcutaneous fat. Disease activity was measured in RA patients using the DAS28-based CRP and ESR \[[@CR33]\].

Laboratory techniques and procedures {#Sec6}
------------------------------------

We obtained venous blood samples that were allowed to clot at room temperature and were subsequently centrifuged at 1,500 relative centrifugal force (RCF) (Rotanta 460R, Andreas Hettich GmbH & Co. KG. Germany) for ten minutes. The serum was stored at −70 °C until analysis.

ESR was measured using the Wintrobe method \[[@CR32]\]. CRP, rheumatoid factor (RF) and glucose levels were measured by standard techniques (RANDOX Laboratories Limited, Crumlin, UK). Serum insulin (limit of detection 0.399 μΙU/mL, ALPCO Diagnostics, Salem, NH, USA), sLep and sLepR limit of detection 0.4 ng/mL and tumor necrosis factor α (TNFα), limit of detection of 8.43 pg/mL (Enzo Life Sciencies, Inc. New York, NY, USA) and, anti-CCP antibodies, U/mL (Axis-Shield Diagnostics Ltd., Dundee, Scotland), were measured by the ELISA method. We put forward the follow new indexes as indicators of leptin production: 1) sLep (ng/mL)/sLepR (ng/mL), 2) sLep (ng/mL)/fat mass (kg) and 3) sLepR (ng/mL)/fat mass (kg).

Homeostasis model assessment-insulin resistance (HOMA-IR) was calculated \[[@CR34]\] and individuals were classified by Stern criteria as: individuals with insulin resistance (IR) when BMI ≥27.5 kg/m^2^ and HOMA-IR ≥3.6 or HOMA-IR \>4.65 independent of BMI, and individuals without IR when negative for one of the two conditions \[[@CR35]\].

Statistical analysis {#Sec7}
--------------------

Data were analyzed with the software SPSS v22.0 (SPSS Inc., Chicago, IL, USA). Results are represented as mean ± SD or frequencies, accordingly. Continuous variables were analyzed with Student's *t* test or the Mann-Whitney *U* test, accordingly. Qualitative variables were analyzed with the chi square (χ^2^) or Fisher's exact test. The Pearson *r* correlation coefficient was calculated. One-way analysis of variance (ANOVA) with Dunnet's T3 post hoc test was used to compare quantitative data between groups. Statistical significance was considered when *P* \<0.05.

Results {#Sec8}
=======

Demographic and clinical characteristics {#Sec9}
----------------------------------------

We evaluated 64 RA patients compared with 66 controls matched by age and gender, classified according to BMI. Age, gender, laboratory tests and metabolic parameters are described in Table [1](#Tab1){ref-type="table"}.Table 1Demographic and clinical characteristics of the groups studiedNormal weightPreobeseObeseMeasurementControlRA*P*ControlRA*P*ControlRA*P*n = 21n = 21n = 26n = 21n = 19n = 22Age, years34 ± 1139 ± 120.12743 ± 1247 ± 100.23046 ± 941 ± 90.076Body weight, kg60 ± 757 ± 60.12668 ± 669 ± 50.57891 ± 1882 ± 90.060BMI, kg/m^2^22.00 ± 1.7822.13 ± 2.270.84527.26 ± 1.1627.50 ± 1.280.49835.03 ± 6.7933.55 ± 2.750.384Body fat mass, %26.36 ± 5.6625.95 ± 6.790.83436.20 ± 3.2436.21 ± 3.210.99138.78 ± 8.1942.35 ± 5.000.095Body fat mass, kg15.86 ± 3.8714.67 ± 4.290.35324.54 ± 4.8424.88 ± 3.240.78435.58 ± 12.0134.81 ± 7.170.806Body fat ratio, kg/m^2^5.83 ± 1.475.80 ± 1.830.9589.94 ± 1.549.97 ± 1.150.94213.86 ± 5.2514.29 ± 2.600.739VFA, cm^2^46.38 ± 26.5877.12 ± 43.280.02181.26 ± 23.62119.52 ± 35.22\<0.001106.43 ± 30.24131.83 ± 21.970.036S4ST, mm52.08 ± 13.6749.17 ± 14.480.513105.94 ± 20.7970.56 ± 19.21\<0.00190.06 ± 16.9476.34 ± 23.010.015ESR, mm/h9.76 ± 6.3219.38 ± 9.820.00121.19 ± 10.0817.10 ± 12.140.21314.21 ± 10.2027.33 ± 14.08\<0.001CRP, mg/L5.22 ± 2.727.66 ± 7.080.1533.56 ± 3.078.83 ± 6.670.0058.66 ± 4.7011.02 ± 9.190.112Glucose mg/dL94.43 ± 14.0396.90 ± 14.270.57493.42 ± 27.18100.80 ± 16.330.223101.37 ± 11.3698.25 ± 10.810.386Insulin, μΙU/mL6.97 ± 6.9714.43 ± 10.820.0059.98 ± 6.5614.76 ± 16.540.26812.81 ± 8.3523.16 ± 44.600.240HOMA-IR1.49 ± 1.163.61 ± 2.980.0032.34 ± 1.594.34 ± 4.980.1713.28 ± 2.255.58 ± 10.920.278Leptin, ng/mL30.14 ± 20.6945.98 ± 40.260.11935.48 ± 12.32121.65 ± 106.350.00179.11 ± 45.20188.21 ± 100.88\<0.001sLepR, ng/mL68.81 ± 24.0260.02 ± 18.810.20943.98 ± 15.2451.34 ± 12.510.13144.75 ± 14.9137.49 ± 9.670.096Leptin/sLepR0.53 ± .500.98 ± 1.400.1760.89 ± 0.412.45 ± 2.450.0332.18 ± 1.625.67 ± 3.560.002Leptin/FM, ng/mL/kg1.87 ± 1.213.04 ± 1.950.0271.41 ± 0.4234.99 ± 4.480.0022.18 ± 1.195.32 ± 2.67\<0.001sLepR/FM, ng/mL/kg4.59 ± 1.894.56 ± 2.330.9641.83 ± 0.712.12 ± 0.530.1961.49 ± 0.951.10 ± 0.410.113Continuous variables are represented by mean ± standard deviation; means were compared with Student's *t* test. *RA* rheumatoid arthritis, *BMI* body mass index, *VFA* visceral fat area, *S4AP* sum of four skinfold thicknesses (bicipital, tricipital, subscapular and supra-iliac), *ESR* erythrocyte sedimentation rate, *CRP* C-reactive protein, *sLepR* soluble leptin receptor), *FM* fat mass, *HOMA-IR* homeostatic model assessment-insulin resistance

In patients with RA, fat mass distribution was different to that in controls; RA patients had an increased VFA and lower subcutaneous adipose tissue accumulation (S4ST) than controls despite having similar BMI. In addition, we observed a trend for increased basal insulin and HOMA-IR in patients with RA vs. controls (Table [1](#Tab1){ref-type="table"}).

RA patients had higher levels of sLep (115.91 ± 103.81 ng/mL vs*.* 46.33 ± 34.66 ng/mL, *P* \<0.001) and higher sLep/fat mass ratio (4.42 ± 1.02 ng/mL/kg vs. 1.79 ± 1.02 ng/mL/kg, *P* \<0.001) than controls. There was no difference in serum sLepR between RA patients and controls (2.75 ± 2.08 ng/mL vs. 2.63 ± 1.86 ng/mL, *P* = 0.755), data not shown.

We observed an increase in sLep levels and sLep/sLepR ratio in obese and preobese RA patients in comparison with controls. In addition, sLep levels and sLep/sLepR ratio in RA patients were increased by fourfold to fivefold in obese patients in comparison with normal-weight patients. Patients with RA had more sLep per fat mass than controls, according to the WHO classification (Table [1](#Tab1){ref-type="table"}).

The prevalence of IR, sLep and sLepR levels and sLep/sLepR ratio in RA patients were as follows: obese \> preobese \> normal weight, while for ESR levels they were obese \> preobese RA patients (Table [2](#Tab2){ref-type="table"}).Table 2Demographic and clinical characteristics of RA patients according to BMIMeasurementAllNormal weightPreobeseObeseBMI 18.50--24.99 kg/m^2^BMI 25.00--29.99 kg/m^2^BMI ≥30.00 kg/m^2^n = 64n = 21n = 21n = 22Female gender, n (%)60 (93.8)19 (90.5)20 (95.2)21 (95.5)Time of disease evolution, years5.34 ± 6.975.73 ± 8.955.06 ± 4.805.23 ± 6.78Positive anti-CCP, n (%)46 (71.9)15 (71.4)13 (61.9)18 (81.8)Anti-CCP, U/Ml167.20 ± 305.49179.03 ± 405.53218.45 ± 338.76107.00 ± 86.53Positive RF, n (%)41 (65.1)13 (61.9)15 (71.4)13 (61.9)RF, UI/Ml79.39 ± 51.5793.03 ± 43.2679.65 ± 60.0968.01 ± 47.61ESR, mm/h21.27 ± 12.7419.38 ± 9.8217.10 ± 12.1427.33 ± 14.08^b^CRP, mg/L9.14 ± 7.717.66 ± 7.088.83 ± 6.6711.02 ± 9.19DAS-28-based CRP3.40 ± 1.302.90 ± 1.203.82 ± 1.243.53 ± 1.36TNFα, pg/Ml57.05 ± 39.8762.03 ± 34.4060.93 ± 53.8248.83 ± 27.48sLep, ng/Ml119.70 ± 104.6445.98 ± 40.26^a^121.65 ± 106.35188.21 ± 100.88sLepR, ng/Ml50.45 ± 17.2560.02 ± 18.81^c^51.34 ± 12.5137.49 ± 9.67sLep/sLepR, ng/mL2.87 ± 3.190.98 ± 1.40^a^2.45 ± 2.455.67 ± 3.56Insulin resistance, n (%)18 (36.7)5 (26.3)5 (35.7)8 (50.0)Continuous variables are represented as mean ± standard deviation; qualitative variables are represented as number (%). Groups were compared with one-way analysis of variance and Dunnet's T3 post hoc test. ^a^Normal weight vs. preobese and obese; ^b^preobese vs. obese; ^c^Normal weight vs. obese. *BMI* body mass index, *anti-CCP* anti-cyclic citrullinated peptide antibodies, *RF* rheumatoid factor, *ESR* erythrocyte sedimention rate, *CRP* C-Reactive protein, *TNF* tumor necrosis factor, *sLep* soluble leptin), *sLepR* soluble leptin receptor, *HOMA-IR* homeostatic model assessment, *DAS-28* disease activity index in 28 joints

In serum sLep from obese RA patients, the sLep/sLepR ratio and sLep/fat mass ratio were higher according to positivity for anti-CCP antibodies (Table [3](#Tab3){ref-type="table"}). In contrast, levels of sLepR were lower with greater BMI (Fig. [1](#Fig1){ref-type="fig"} and Table [3](#Tab3){ref-type="table"}).Table 3sLep, sLepR and respective fat mass ratios of RA patients according to BMI and anti-CCP statusNormal weightPreobeseObeseBMI 18.50--24.99 kg/m^2^BMI 25.00--29.99 kg/m^2^BMI ≥30.00 kg/m^2^*Anti-CCP*MeasurementNegativePositive*P*NegativePositive*P*NegativePositive*P*n = 6n = 15n = 8n = 13n = 4n = 18sLep, ng/Ml51.09 ± 29.7643.93 ± 44.540.26766.90 ± 51.78155.34 ± 118.560.104104.04 ± 29.21206.91 ± 101.910.033sLepR, ng/Ml60.46 ± 14.2059.82 ± 21.130.89856.47 ± 13.7948.49 ± 11.550.51845.89 ± 4.6335.39 ± 9.550.101sLep/sLepR, ng/Ml0.89 ± .491.02 ± 1.690.2441.36 ± 1.433.05 ± 2.750.2402.13 ± 0.866.55 ± 3.430.048sLep/fat mass, ng/mL/kg3.44 ± 1.722.86 ± 2.080.5642.73 ± 2.306.39 ± 4.980.0533.27 ± 0.875.77 ± 2.730.033sLepR/fat mass, ng/mL/kg4.11 ± 1.014.78 ± 2.790.9252.25 ± 0.651.99 ± 0.430.5291.45 ± 0.271.01 ± 0.390.101Continuous variables are represented as mean ± standard deviation; the Mann-Whitney *U* test was used to compare differences between groups. *BMI* body bas index, *anti-CCP* anti-cyclic citrullinated peptide antibodies, *sLep* serum leptin, *sLepR* soluble leptin receptor)Fig. 1Serum leptin (*sLep*), sLep/sLep receptor (*sLepR*) and leptin/fat mass ratio in controls and patients with rheumatoid arthritis (RA) according to anti-cyclic citrullinated peptide antibodies (*anti-CCP*). Mean ± standard deviation of sLep (**a**), sLepR (**b**), leptin/sLepR (**c**), leptin/fat mass ratio (**d**) and sLepR/fat mass ratio (**e**)

sLep, sLepR and sLep/sLepR were strongly correlated with fat mass, BMI, insulin and HOMA-IR, as is shown in Table [4](#Tab4){ref-type="table"}. Levels of sLep were positively correlated with ESR (Table [4](#Tab4){ref-type="table"}). There was no correlation between sLep or sLepR and other parameters including anti-CCP antibodies. Notwithstanding, analysis of partial correlation showed that anti-CCP antibodies were correlated with sLep/fat mass ratio (partial *r* = 0.347, *P* = 0.033) after adjustment for age, S4ST and fat mass.Table 4Correlation between anti-CCP, leptin, sLepR, or leptin/sLep, and adiposity, inflammatory and metabolic markersAnti-CCPsLepsLepRsLep/sLepRMeasurement*RrrrPPPP*BMI, kg/m^2^−0.1540.494−0.4720.5560.221\<0.001\<0.001\<0.001Body fat mass, %−0.1740.570−0.4580.5870.166\<0.001\<0.001\<0.001ESR, mm/h0.1370.257−0.2590.3550.2940.0330.059\<0.001CRP, mg/L0.2930.063−0.1770.0920.0210.5970.2050.515sLep, ng/Ml−0.004-−0.5570.9400.977\<0.001\<0.001sLepR, ng/Ml−0.1340.613-−0.7400.354\<0.001\<0.001Insulin μUI/Ml−0.0830.427−0.1480.3140.5670.0010.286\<0.001HOMA-IR−0.0910.416−0.0720.2360.5330.0020.6070.092Pearson *r* coefficient was calculated. *Anti-CCP* anti cyclic citrullinated peptide antibodies, *BMI* body mass index, *ESR* erythrocyte sedimentation rate, *CRP* C-reactive protein, *DAS-28* disease activity index in 28 joints, *sLepR* soluble leptin receptor, *FM* fat mass, *HOMA-IR*, homeostatic model assessment-insulin resistance. *RF* rheumatoid factor

sLep and sLepR quartiles {#Sec10}
------------------------

When we classified sLep level by quartiles, we observed increasing ESR, body fat ratio, HOMA-IR and decreasing sLepR level. When we grouped the sLepR level by quartiles, we observed increasing ESR, body fat ratio, DAS28 ESR and DAS28 CRP (Table [5](#Tab5){ref-type="table"}).Table 5Adiposity, metabolic and inflammation markers in RA patients grouped by sLep and sLepR quartilessLep ng/MlQuartile 1Quartile 2Quartile 3Quartile 4\<36.2736.27--72.7572.76 --177.48\>177.48n = 14n = 16n = 17n = 17Body fat ratio, kg/m^2^5.92 ± 2.428.34 ± 2.9011.16 ± 2.5813.82 ± 3.43ESR, mm/h18.37 ± 10.5319.37 ± 11.7620.17 ± 13.1427.17 ± 13.65HOMA-IR2.23 ± 2.113.52 ± 3.983.4 ± 2.558.25 ± 13.32sLepR, ng/Ml69.30 ± 17.6248.24 ± 7.5047.21 ± 11.4836.48 ± 12.49sLepR ng/MlQuartile 4Quartile 3Quartile 2Quartile 1\>59.3548.74--59.3438.83--48.73\<38.83n = 11n = 14n = 11n = 15Body fat ratio, kg/m^2^6.59 ± 2.638.77 ± 2.569.30 ± 4.4911.59 ± 4.73ESR, mm/h15.91 ± 9.2618.14 ± 10.5219.50 ± 9.9027.94 ± 12.64DAS-28 (ESR)3.08 ± 1.463.09 ± 1.253.74 ± 1.054.02 ± 1.45DAS-28 (CRP)2.86 ± 1.372.82 ± 1.193.39 ± 1.063.64 ± 1.43*FMI* fat mass index, *ESR* erythrocyte sedimentation rate, *HOMA-IR* homeostatic model assessment insulin resistance, *sLepR* soluble leptin receptor, *DAS-28* disease activity score in 28 joints, *CRP* C-reactive protein

Discussion {#Sec11}
==========

In this study, we observed greater sLep levels and sLep/sLepR ratio in RA patients compared to age-, gender- and BMI-matched controls (Table [1](#Tab1){ref-type="table"}); these associations were more evident in RA patients who were overweight or obese (Table [2](#Tab2){ref-type="table"}). After normalization of sLep with fat mass (sLep/fat mass ratio), patients with RA also had greater values of sLep (nanograms per milliliter) per kilogram of fat mass in every BMI category (Table [1](#Tab1){ref-type="table"}). Considering this, patients with RA have greater leptin resistance than that observed in obese controls \[[@CR36], [@CR37]\]. sLep, sLep/sLepR ratio and sLep/fat mass ratio in serum from obese RA patients was higher according to positivity for anti-CCP antibodies. Agrawal et al., found that leptin induced the release of IL-6, TNF-α and IL-10 by B lymphocytes, high levels of leptin with high levels of these proinflammatory cytokines, and a chronic inflammatory environment \[[@CR38]\]. In RA proinflammatory cytokines like TNF-α and IL-6 might also increase leptin production by adipocytes, leading to chronic hyperleptinemia and leptin resistance \[[@CR39]\].

This is the first report showing increased leptin production in association with anti-CCP status in preobese and obese RA patients (Fig. [1a](#Fig1){ref-type="fig"}, 1d). This suggests that leptin may be an important mediator for sustaining autoimmune humoral responses in RA, especially in anti-CCP positive patients. Leptin has a myriad of effects triggering or perpetuating acute and chronic inflammation, locally or systemically \[[@CR40]\]. Leptin has a role in innate and adaptive immunity, acting as an anti-inflammatory and proinflammatory mediator. Several studies have been performed to investigate the signaling pathways at the molecular level, to address the pleiotropic activity of leptin. Leptin is able to trigger the phosphorylation of different pathways involving extracellular-signal-regulated kinases (ERK)-1, ERK-2, p38 mitogen-activated protein kinase (MAPK), and phosphoinositide 3-kinase (PI3K) in peripheral blood mononuclear cells (PBMCs) eliciting T cell proliferation. Dendritic cell differentiation is favored by STAT3 phosphorylation induced by leptin \[[@CR41], [@CR42]\]. In adaptive immunity, leptin incentivizes T cell differentiation towards T helper (Th)1 and Th17 effector cells, activation of B cells, and inhibition of T regulatory (T~reg~) cell proliferation \[[@CR43]\].

Leptin blockade in experimental autoimmune encephalomyelitis (EAE) improves clinical score, disease progression and relapses by inhibition of T cell proliferation and cytokine secretion toward a Th2/regulatory profile \[[@CR44]\]. In a report of Amarlyo et al. \[[@CR45]\] leptin levels were increased in lupus patients, and in murine models leptin promotes the survival and proliferation of autoreactive T cells, explained by upregulation of B cell lymphoma 2 protein (Bcl-2).

Some previous reports on leptin in RA did not report correlation with clinical and inflammatory markers like CRP or ESR. The inability to reproduce these findings may be because most of the reported studies did not include enough overweight or obese patients and did not considered the fat mas distribution or the sLep/fat mass ratio \[[@CR46]--[@CR48]\].

In addition to the leptin resistance state observed in our obese RA patients, we observed an association but no correlation between anti-CCP antibodies and increased sLep, sLep/sLepR and sLep/fat mass ratios according to BMI (Fig. [1a, c, d](#Fig1){ref-type="fig"}). Notwithstanding, analysis of partial correlation showed that after controlling for age, fat mass and subcutaneous fat (S4ST) there was an association between serum titers of anti-CCP and sLep (partial *r* = 0.347, *P* = 0.033).

Anti-CCP antibodies are highly specific for RA. Published data suggest distinct pathogenic mechanisms underlying anti-CCP-positive RA \[[@CR49]\]. RA patients positive for anti-CCP antibodies have more aggressive disease with early radiographic changes \[[@CR49], [@CR50]\]. In the context of a proinflammatory state or autoimmune condition such as RA, leptin could be a stimulator of B cells and plasma cells to produce higher titers of anti-CCP antibodies \[[@CR51]\].

After classifying patients by sLep and sLepR quartiles we observed, a trend for higher ESR, and CRP-based and ESR-based DAS-28 with greater sLep and lower sLepR levels. The former observations suggest that other molecular pathways/molecules might be involved in the regulation of leptin in RA but also the possible involvement of leptin in the loss of immune tolerance towards citrullinated proteins in RA. We suggest that leptin could be a surrogate marker of severity or chronicity of humoral immunity in RA in the presence of obesity.

Despite the intensive study of leptin in RA, there are no reports on the association between sLep and anti-CCP antibodies. We consider this study is relevant to open new research fields to allow further examination of the role of these molecules in the pathogenesis of RA. In addition, it is important to evaluate the activity of enzymes such as PADI4 and Dickkopf-1 (DKK-1) in order to improve the characterization of the leptin pathway in RA.

Conclusions {#Sec12}
===========

In preobese and obese RA patients there is increased production of sLep according to anti-CCP positivity. This phenomenon suggests there is an additive effect of chronic inflammation resulting from RA and obesity in which leptin favors the humoral response against citrullinated proteins. In summary, the data observed in our study suggest sLep could be a surrogate marker of chronicity and humoral immunity in RA in the presence of obesity.
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